Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes results 2025 nejm The SOUL Study orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes results 2025 nejm The SOUL Study ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes results 2025 nejm The SOUL Study, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes results 2025 nejm The SOUL Study in your area.
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
28.19
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
22.38
SELECT Trial
26.72
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with
26.76
Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results
25.59
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
20.92
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy
29.54
